Conduit Pharmaceuticals Inc (CDT) EV/EBITDA Multiple

Conduit Pharma (CDT) - corporate logo

Conduit Pharmaceuticals management is currently adapting operational processes by engaging counterparties to transfer rights for medical developments. Conduit Pharmaceuticals possesses significant market influence by acquiring promising molecules from industry behemoths, which ensures inelastic demand. Serving as the primary valuation tool, this chart of quotes on GURU.Markets demonstrates an EV/EBITDA ratio of 0.00. The business's success is based on clinical test results and the efficiency of commercializing forgotten assets.

CDT Conduit Pharmaceuticals Inc: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/10/2026

CDT (conduitpharma.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price Conduit Pharma|CDT - Analyst Median Target
- market capitalization details:
Market Capitalization Conduit Therapeutics|CDT - Business Value
- issuer book value statistics:
Net Assets per Single Share Conduit Pharmaceuticals|CDT - Accounting Capitalization|Market Capitalization to Book Value Ratio conduitpharma.com|CDT - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Conduit Pharmaceuticals|CDT - Long-Term Liabilities to Capital|Short-Term Debt to Capital Conduit Pharmaceuticals Inc.|CDT - Company Total Debt|Debt to Book Capitalization Ratio Conduit Therapeutics|CDT - Long-Term Debt|Company Short-Term Debt Conduit Pharmaceuticals|Quick Ratio conduitpharma.com
- business earnings and investment ratios data:
CDT - Company Profit|Future Profit Conduit Pharmaceuticals|CDT - P/E Multiple|Forward P/E Multiple Conduit Pharmaceuticals|CDT - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Conduit Therapeutics|CDT - Company profit before taxes, interest and amortization|Net earnings per share for the last 12 months Conduit Pharmaceuticals|CDT - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months conduitpharma.com|CDT - Earnings per share trend in current year|Earnings growth forecast for next year Conduit Pharmaceuticals
Analysis of all company metrics:CDT (Conduit Pharma)
Manufactured products of conduitpharma.com

For Conduit Pharmaceuticals (CDT), whose valuation is based on AstraZeneca licenses without current revenue, accounting for debt in the overall valuation is critical. This metric compares the total enterprise value with operating profit, stripping the result of tax and debt distortions. By analyzing the business valuation level via the EV/EBITDA multiple on GURU.Markets, an investor can recognize shifts in market cycles before official reports are released.

Competitor analysis

EV/EBITDA Multiple TVTX (Retrophin)|Total Company Value to Operating Income Before Depreciation Ratio Ardelyx Corp (ARDX)|ProKidney Corp. - EV/EBITDA Multiple|AKBA (akebia.com) - Enterprise Value to Operating Income Before Depreciation|Cara Therapeutics (TVRD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation DMAC|UNCY (Unicycive) - EV/EBITDA Multiple|Company Value to EBITDA rockwellmed.com RMTI|Enterprise Value to EBITDA Ratio CVKD (Cadrenal Therapeutics)|CALT - Company Value to EBITDA|EV/EBITDA Multiple RNLX (Renalytix PLC)|ZVSA - Enterprise Value to EBITDA Ratio